Table 2.
Number and Change in Rates of Past-Year Opioid Use Disorder (OUD) and Persons Receiving Medications for Opioid Use Disorder (MOUD) by State: United States, 2010–2019.
| State | Unadjusted OUD prevalence using NSDUH, 2018–2019 No. (Rate) | Adjusted OUD prevalence using NSDUH + multiplier, 2018–2019 No. (Rate) | Total individuals receiving MOUD No. (Rate) | Percent changeb in rate from 2010 to 2019 | Percent change b in rate from 2018 to 2019 |
|---|---|---|---|---|---|
|
| |||||
| Alabama | 44,000 (1,050.9) | 197,560 (4,718.5) | 23,897 (570.8) | 110.0% | 7.0% |
| Alaska | 4,000 (656.9) | 17,960 (2,949.7) | 2,437 (400.2) | 422.4% | 12.3% |
| Arizona | 51,000 (821.8) | 228,990 (3,689.8) | 19,390 (312.4) | 111.3% | 10.2% |
| Arkansas | 11,000 (430.1) | 49,390 (1931.4) | 4,827 (188.8) | 350.9% | 16.0% |
| California | 206,000 (612.3) | 924,940 (2749) | 64,566 (191.9) | 59.3% | 2.4% |
| Colorado | 37,000 (749.6) | 166,130 (3,365.6) | 10,947 (221.8) | 243.9% | 18.5% |
| Connecticut | 14,000 (450.7) | 62,860 (2,023.9) | 28,970 (932.7) | 53.4% | 11.1% |
| Delaware | 10,000 (1,190.7) | 44,900 (5,346.5) | 8,590 (1,022.9) | 147.7% | 3.9% |
| D.C. | 11,000 (1,804) | 49,390 (8,100) | 2,428 (398.2) | −9.2% | 8.1% |
| Florida | 169,000 (903.9) | 758,810 (4,058.7) | 50,258 (268.8) | 94.8% | 2.0% |
| Georgia | 49,000 (545.2) | 220,010 (2,447.8) | 22,793 (253.6) | 99.7% | 1.6% |
| Hawaii | 8,000 (660.6) | 35,920 (2,965.9) | 2,259 (186.5) | 116.4% | −0.2% |
| Idaho | 12,000 (802.5) | 53,880 (3,603) | 2,934 (196.2) | 207.8% | 10.8% |
| Illinois | 50,000 (461.3) | 224,500 (2,071.5) | 26,729 (246.6) | 69.4% | 6.6% |
| Indiana | 48,000 (841.4) | 215,520 (3,777.7) | 24,526 (429.9) | 134.9% | 7.8% |
| Iowa | 21,000 (784.7) | 94,290 (3,523.2) | 2,514 (93.9) | 235.8% | 5.6% |
| Kansas | 15,000 (611.8) | 67,350 (2,747.1) | 3,913 (159.6) | 97.8% | −2.4% |
| Kentucky | 55,000 (1,445) | 246,950 (6,488.2) | 31,047 (815.7) | 389.3% | 2.4% |
| Louisiana | 35,000 (892.1) | 157,150 (4,005.5) | 15,418 (393) | 114.5% | 0.9% |
| Maine | 15,000 (1,265.9) | 67,350 (5,683.9) | 11,609 (979.7) | 69.7% | 4.6% |
| Maryland | 22,000 (426.1) | 98,780 (1,913.3) | 41,389 (801.7) | 82.7% | 1.7% |
| Massachusetts | 45,000 (747.9) | 202,050 (3,358.1) | 50,354 (836.9) | 112.8% | −0.7% |
| Michigan | 33,000 (383.9) | 148,170 (1,723.9) | 32,717 (380.7) | 119.0% | 6.9% |
| Minnesota | 8,000 (167.4) | 35,920 (751.8) | 11,048 (231.2) | 126.8% | 2.7% |
| Mississippi | 11,000 (436.3) | 49,390 (1,958.8) | 6,774 (268.7) | 170.9% | 3.9% |
| Missouri | 23,000 (439.3) | 103,270 (1,972.4) | 10,684 (204.1) | 130.2% | 10.9% |
| Montana | 9,000 (980.8) | 40,410 (4,403.9) | 2,435 (265.4) | 330.5% | −2.8% |
| Nebraska | 5,000 (309.1) | 22,450 (1,388) | 1,546 (95.6) | 100.9% | 6.2% |
| Nevada | 22,000 (839.1) | 98,780 (3,767.6) | 5,229 (199.4) | 101.7% | 7.2% |
| New Hampshire | 9,000 (750.9) | 40,410 (3,371.5) | 9,142 (762.7) | 156.6% | −0.6% |
| New Jersey | 69,000 (905.7) | 309,810 (4,066.6) | 32,987 (433) | 66.1% | 2.3% |
| New Mexico | 10,000 (559.5) | 44,900 (2,512) | 10,159 (568.4) | 265.9% | 1.3% |
| New York | 77,000 (459.1) | 345,730 (2,061.2) | 77,303 (460.9) | 38.1% | 7.4% |
| North Carolina | 60,000 (667.7) | 269,400 (2,998.2) | 39,413 (438.6) | 140.8% | 4.2% |
| North Dakota | 7,000 (1,098.5) | 31,430 (4,932.2) | 1,230 (193) | 904.3% | 38.5% |
| Ohio | 143,000 (1,429.9) | 642,070 (6,420.2) | 48,133 (481.3) | 286.7% | 3.5% |
| Oklahoma | 17,000 (511.2) | 76,330 (2,295.5) | 11,028 (331.6) | 146.9% | 14.0% |
| Oregon | 32,000 (877.2) | 143,680 (3,938.8) | 13,616 (373.3) | 140.2% | 12.0% |
| Pennsylvania | 72,000 (649.7) | 323,280 (2,917.3) | 72,197 (651.5) | 132.6% | 8.5% |
| Rhode Island | 5,000 (539.1) | 22,450 (2,420.5) | 9,290 (1,001.6) | 110.7% | −0.6% |
| South Carolina | 12,000 (271.5) | 53,880 (1,219) | 14,686 (332.3) | 125.5% | 6.4% |
| South Dakota | 2,000 (271) | 8,980 (1,216.6) | 488 (66.1) | 1846.7% | 33.8% |
| Tennessee | 50,000 (856.8) | 224,500 (3847.1) | 29,819 (511) | 161.6% | −1.2% |
| Texas | 51,000 (211.6) | 228,990 (950.1) | 32,711 (135.7) | 71.1% | 5.9% |
| Utah | 14,000 (540.1) | 62,860 (2,424.9) | 9,458 (364.9) | 68.1% | 3.5% |
| Vermont | 7,000 (1,270.5) | 31,430 (5,704.7) | 7,397 (1,342.6) | 191.7% | 6.6% |
| Virginia | 48,000 (656.9) | 215,520 (2,949.5) | 21,980 (300.8) | 160.2% | 6.8% |
| Washington | 57,000 (876.8) | 255,930 (3,936.8) | 31,050 (477.6) | 193.3% | 11.8% |
| West Virginia | 12,000 (770.3) | 53,880 (3,458.6) | 15,576 (999.8) | 117.5% | 0.1% |
| Wisconsin | 24,000 (480) | 107,760 (2,155.3) | 13,308 (266.2) | 116.6% | 11.4% |
| Wyoming | 3,000 (611.3) | 13,470 (2,744.9) | 760 (154.9) | 276.5% | 4.1% |
| United States | 1,824,000 (650.9) | 7,631,804 (2,723.5) | 1,023,959 (365.4) | 105.6% | 4.9% |
Note. MOUD=Medications for Opioid Use Disorder.
Source. Unadjusted OUD prevalence from the National Survey on Drug Use and Health, adjusted OUD prevalence using Keyes et al. 2022 multiplier method, derived from capture-recapture data from the state of Massachusetts, (Barocas et al., 2018) which estimated OUD rates were 4.49 times higher than the NSDUH state-level estimates in 2015. Number of individuals receiving MOUD obtained by combining pharmacy dispensed buprenorphine from IQVIA and number of clients in opioid treatment programs using the National Survey of Substance Abuse Treatment Services.
Rates are per 100 000 people aged ≥ 12 years.
Percent change in rates; State-specific MOUD rates for 2010 and 2018 located in Appendix Table 3.
Total individuals receiving MOUD excludes those receiving naltrexone dispensed in pharmacies.